Pivotal Data on Bronchial Thermoplasty from the Asthma Intervention Research 2 (AIR2) Trial to be Presented at ATS 2009
Posted on: Wednesday, 6 May 2009, 11:14 CDT
New non-drug procedure for severe asthma featured in eight presentations at annual conference in
"We're looking forward to an exciting ATS meeting with numerous scientific presentations focusing on bronchial thermoplasty and its potential to elevate the standard of care for patients suffering from severe asthma," said
The full schedule of oral and poster presentations surrounding bronchial thermoplasty at
About Bronchial Thermoplasty Delivered by the Alair System
Bronchial thermoplasty is a novel non-drug treatment for asthma. The treatment is performed through the working channel of a standard flexible bronchoscope that is introduced through a patient's nose or mouth, and into their lungs. The tip of the small diameter Alair Catheter is expanded to contact the walls of targeted airways. Controlled thermal energy is then delivered to the airway walls to reduce the amount of airway smooth muscle that narrows the airways in patients with asthma during an asthma attack. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under light anesthesia and the patient returns home the same day. In the period immediately following bronchial thermoplasty, there is an expected increase and worsening of respiratory-related symptoms, which are of the type expected following bronchoscopy in patients with asthma. These typically occur within a day of the procedure and resolve on average within 7 days with standard care.
CAUTION: Alair System is an Investigational Device. It is limited by
Alair is a registered trademark of Asthmatx, Inc.
About Asthmatx
Asthmatx is developing catheter-based medical devices for the treatment of asthma. Asthmatx has developed the Alair System to perform an investigational outpatient procedure called bronchial thermoplasty. The Alair System from Asthmatx was awarded "Best of 2006" by Popular Science Magazine and bronchial thermoplasty was named one of the "Top Ten Medical Innovations for 2007" by the prestigious Cleveland Clinic Foundation. The Alair System has received a CE Mark for use in the European Union. For more information on Asthmatx visit www.asthmatx.com.
SOURCE Asthmatx
Source: PR Newswire
Related Articles
- Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair(R) System for Severe Asthma
- 'Difficult-To-Treat Asthma' May Be Due To Difficult-To-Treat Patients
- New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients
- Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients With Type 1 and Type 2 Diabetes
- CORRECTING and REPLACING Data Highlighting Cambridge Heart's Non-Invasive HearTwave(R) II System to Be Presented in Late Breaker at American College of Cardiology Meeting
- CardiacAssist Announces 800th TandemHeart System Procedure
- VeriChip Corporation's VeriMed System for Patient Identification Selected By 13 New Hospitals; 97 Healthcare Facilities Have Now Agreed to Implement the VeriMed Patient Identification System
- Coronary Artery Dilation Among Patients Presenting With Systemic- Onset Juvenile Idiopathic Arthritis
- Early Life Risk Factors for Current Wheeze, Asthma, and Bronchial Hyperresponsiveness at 10 Years of Age*
- FlowMedica Announces New Physician-Sponsored Study of Its Benephit Infusion System in Patients With Renal Insufficiency
 |
 |
User Comments (0)
RSS Feeds